GSK launches savings drive to invest in drug pipeline

GSK has today launched a £1.9 billion cost-savings drive to help fund the British drugmaker's expanded late-stage study roster, aiming to deliver on CEO Luke Miels' promise of faster drug development and boost investor trust.